2024

• Levin, Nina; Killingberg, Kristin Toftaker; Grønberg, Bjørn Henning; Halvorsen, Tarje Onsøien. (2024) Evaluation of Radiation Therapy Treatment Plans in a Randomized Phase 2 Trial Comparing 2 Schedules of Twice-Daily Thoracic Radiation Therapy in Limited Stage Small Cell Lung Cancer. International Journal of Radiation Oncology, Biology, Physics
  Academic article
• Graabak, Gustav; Killingberg, Kristin Toftaker; Grønberg, Bjørn Henning; Halvorsen, Tarje Onsøien. (2024) Effect of FDG PET-CT for Staging and Radiotherapy Planning – A Comparison of Cohorts From Two Randomized Trials of Thoracic Radiotherapy in Limited-Stage SCLC. JTO Clinical and Research Reports
  Academic article

2023

• Killingberg, Kristin Toftaker; Grønberg, Bjørn Henning; Jordhøy, Marit Slaaen; Kirkevold, Øyvind; Halvorsen, Tarje Onsøien. (2023) Treatment Outcomes of Older Participants in a Randomized Trial Comparing Two Schedules of Twice-Daily Thoracic Radiotherapy in Limited-Stage SCLC. Journal of Thoracic Oncology
  Academic article
• Taranova, Evgenia; Grønberg, Bjørn Henning; Halvorsen, Tarje Onsøien; Killingberg, Kristin Toftaker; Slaaen, Marit; Aanerud, Marianne. (2023) Associations between patient-reported nutritional status, survival, and toxicity among patients with limited stage small-cell lung cancer (LS SCLC) in a randomized trial of high-dose, twice-daily (BID) thoracic radiotherapy (TRT). Journal of Clinical Oncology
  Abstract
• Grønberg, Bjørn Henning; Killingberg, Kristin Toftaker; Fløtten, Øystein; Bjaanæs, Maria Moksnes; Madebo, Tesfaye; Schytte, Tine. (2023) Final survival data from a randomized phase II trial comparing high-dose with standard-dose twice-daily (BID) thoracic radiotherapy (TRT) in limited stage small-cell lung cancer (LS SCLC). Journal of Clinical Oncology
  Abstract
• Grønberg, Bjørn Henning; Killingberg, Kristin Toftaker; Halvorsen, Tarje Onsøien. (2023) Final survival data from a randomized phase II trial comparing high-dose with standard-dose twice-daily (BID) thoracic radiotherapy (TRT) in limited stage small-cell lung cancer (LS SCLC). American Journal of Clinical Oncology
  Abstract
• Killingberg, Kristin Toftaker. (2023) Twice-daily thoracic radiotherapy in limited stage small-cell lung cancer. NTNU Grafisk senter
  Doctoral dissertation

2022

• Stokke, Kristin; Sandvei, Marie Søfteland; Grønberg, Bjørn Henning; Jordhøy, Marit Slaaen; Killingberg, Kristin Toftaker; Halvorsen, Tarje Onsøien. (2022) Prognostic Value of Post First-Line Chemotherapy Glasgow Prognostic Score in Advanced Non-Small Cell Lung Cancer. Clinical Medicine Insights: Oncology
  Academic article
• Killingberg, Kristin Toftaker; Halvorsen, Tarje Onsøien; Fløtten, Øystein; Brustugun, Odd Terje; Langer, Seppo W.; Nyman, Jan. (2022) Patient-reported health-related quality of life from a randomized phase II trial comparing standard-dose with high-dose twice daily thoracic radiotherapy in limited stage small-cell lung cancer. Lung Cancer
  Academic article
• Stokke, Kristin; Halvorsen, Tarje Onsøien; Grønberg, Bjørn Henning; Saltvedt, Ingvild; Jordhøy, Marit Slaaen; Kirkevold, Øyvind. (2022) Associations between Measured and Patient-Reported Physical Function and Survival in Advanced NSCLC. Healthcare
  Academic article
• Levin, Nina; Danielsen, Signe; Halvorsen, Tarje Onsøien; Killingberg, Kristin Toftaker; Redalen, Kathrine Røe; Grønberg, Bjørn Henning. (2022) Comparing target volumes in a randomized trial of high-dose radiotherapy in small cell lung cancer. Radiotherapy and Oncology
  Abstract

2021

• Grønberg, Bjørn Henning; Killingberg, Kristin Toftaker; Fløtten, Øystein; Brustugun, Odd; HORNSLIEN, KJERSTI; Madebo, Tesfaye. (2021) High-dose versus standard-dose twice-daily thoracic radiotherapy for patients with limited stage small-cell lung cancer: an open-label, randomised, phase 2 trial. The Lancet Oncology
  Academic article

2020

• Halvorsen, Tarje Onsøien; Stokke, Kristin; Killingberg, Kristin Toftaker; Raj, Sunil Xavier; Sørhaug, Sveinung; Brustugun, Odd Terje. (2020) Randomized phase III trial comparing switch-maintenance pemetrexed with observation followed by pemetrexed at progression in advanced NSCLC. Acta Oncologica
  Academic article